ERBB2 and gastric cancer: Consequently, this unique HER2-targeted strategy demonstrated stronger synergistic tumor growth inhibitory effect in gastric cancer cell lines (Fig. 3a–e), CDX models (Fig. 4a, b) and PDX models with 3 + HER2 expression compared to HLX02 and HLX11 combination treatment (Fig. 4c, d).